CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41 st Annual Strategic ...

“It is the unsung hero of the whole thing,” says Giuseppe Ciaramella, who was head of infectious diseases at Moderna from 2014 to 2018. The vaccines, appropriately celebrated as a first for ...

A Moderna anunciou nesta quarta-feira (21) que retirou voluntariamente o pedido de aprovação junto à agência reguladora dos Estados Unidos (FDA, na sigla em inglês) para sua vacina combinada ...

FILE – A vial of Moderna COVID-19 vaccine rests on a table at an inoculation station in Jackson, Miss., on July 19, 2022. (AP Photo/Rogelio V. Solis, File) A combination shot for flu and Covid ...

Moderna initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock experienced a 3 ...

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country against future pandemics. The Moderna Innovation and Technology Centre (MITC ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other growth stocks. The market closed last week mostly lower, however, the S&P 500 has been up ...

If you’re on the fence about investing in Moderna, Inc., Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

Moderna, the biotech company behind one of the original mRNA COVID-19 vaccines, is undergoing an AI-powered workplace transformation. In partnership with OpenAI, Moderna has created thousands of ...

Moderna will combine its technology and HR departments, inspired by their increasing reliance on generative AI and ongoing OpenAI partnership. The biotech giant currently uses over 3,000 versions ...